Why the study?
Anticancer therapies carry risks of cardiovascular toxicity, including acute or late-onset heart failure, despite improving cancer prognosis.
What are the mechanisms and clinical presentations of left ventricular dysfunction induced by old and new cardiotoxic drugs in cancer patients?
What are the mechanisms and clinical presentations of left ventricular dysfunction induced by old and new cardiotoxic drugs in cancer patients?
This review highlights the mechanisms of cardiotoxicity from both traditional and novel anticancer therapies, emphasizing the high risk of left ventricular dysfunction in cancer survivors.
Answers are grounded in this paper and cite their sources.
Requires vigilant cardiac monitoring in cancer patients; review extends mechanistic insights but leaves open optimal prevention strategies.
Although there have been many improvements in prognosis for patients with cancer, anticancer therapies are burdened by the risk of cardiovascular toxicity. Heart failure is one of the most dramatic clinical expressions of cardiotoxicity, and it may occur acutely or appear years after treatment. This article reviews the main mechanisms and clinical presentations of left ventricular dysfunction induced by some old and new cardiotoxic drugs in cancer patients, referring to the most recent advances in the field. The authors describe the mechanisms of cardiotoxicity induced by anthracyclines, which can lead to cardiovascular problems in up to 48% of patients who take them. The authors also describe mechanisms of cardiotoxicity induced by biological drugs that produce left ventricular dysfunction through secondary mechanisms. They outline the recent advances in immunotherapies, which have revolutionised anticancer therapies.
No takes yet. Share an insight, caveat, or question.
Cuomo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: